Clinical data | |
---|---|
Trade names | Edronax, others |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Norepinephrine reuptake inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ≥94%[2][3] |
Protein binding | 97–98%[2][3] |
Metabolism | Liver (CYP3A4-mediated)[2] |
Elimination half-life | 12–12.5 hours[2][3] |
Excretion | Urine (78%; 9–10% unchanged)[2][3] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H23NO3 |
Molar mass | 313.397 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemate |
| |
| |
(what is this?) (verify) |
Reboxetine, sold under the brand name Edronax among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication marketed as an antidepressant by Pfizer for use in the treatment of major depressive disorder, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD).[4] It is approved for use in many countries worldwide, but has not been approved for use in the United States.[5]
{{cite book}}
: |work=
ignored (help)